Is Lyell Immunopharma Inc (LYEL) overvalued? · rev $61.0K
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
This page asks whether Lyell Immunopharma Inc (LYEL) looks expensive on cached numbers — not a short thesis.
Latest reported LYEL revenue for 2024-12-31 was $61.0K. Net income was -$343.0M. Revenue was down 53.1% from 2023-12-31 to 2024-12-31. LYEL currently screens at market cap $143.5M.
LYEL currently screens at market cap $143.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LYEL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LYEL stock page for the full model, not this heading.
Not investment advice.